Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
Kosmas Alexandros Pervanidis, G D'Angelo, Jörn Weisner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6052-6063
Closed Access | Times Cited: 11

Showing 11 citing articles:

An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
Riccardo Asnaghi, Gabriele Antonarelli, Elena Battaiotto, et al.
Expert Opinion on Pharmacotherapy (2025)
Open Access | Times Cited: 1
Structural Requirements of Isoform-Specific Inhibitors of Akt: Implications in the Development of Effective Cancer Treatment Strategies
Tenzin Adon, Syamal D. Bhattacharya, SubbaRao V. Madhunapantula, et al.
European Journal of Medicinal Chemistry (2025), pp. 117334-117334
Closed Access | Times Cited: 1
Discovery of 5-Phenylthiazol-2-amine Derivatives as Novel PI4KIIIβ Inhibitors with Efficacious Antitumor Activity by Inhibiting the PI3K/AKT Axis
Bichuan Wang, Siyuan Hao, Fang Han, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease
Yu Zhang, Jiahui Yang, Jiali Min, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Hui Tao, Bo Yang, Atena Farhangian, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
The discovery of novel N-heterocyclic-based AKT inhibitors with potential efficacy against prostate cancer
Jinxiao Sun, Dezhi Yang, Yongmi Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117435-117435
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Trametinib and M17, a novel small molecule inhibitor of AKT, display a synergistic antitumor effect in triple negative breast cancer cells through the AKT/mTOR and MEK/ERK pathways
Hongwei Han, Minkai Yang, Zhongling Wen, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107981-107981
Closed Access | Times Cited: 2
Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models
Cheng Long, Hui Shen, Hui Li, et al.
Fundamental and Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Elucidation of the solution structure of macrocyclic paritaprevir and exploration of its antitumor potential through molecular docking
Xiong Zhang, Tong Li, Hongyu Xu, et al.
Journal of Molecular Liquids (2024) Vol. 410, pp. 125682-125682
Closed Access
Latent allosteric control of protein interactions by ATP-competitive kinase inhibitors
David Vaisar, Natalie G. Ahn
Current Opinion in Structural Biology (2024) Vol. 89, pp. 102935-102935
Closed Access
Page 1

Scroll to top